Quintiles Introduces Continuous Glucose Monitoring Services to Improve Diabetes Outcomes

RESEARCH TRIANGLE PARK, N.C. – June 24, 2016 – Quintiles today announced the launch of its new Continuous Glucose Monitoring (CGM) service offering. This new solution combines innovative, wearable technology with Quintiles’ deep therapeutic and analytical expertise to help enhance the efficiency and quality of diabetes-focused clinical trials.

When used in clinical research, the new CGM offering will provide investigators with access to a myriad of customized data analytics and performance reports through its award-winning Quintiles Infosario®technology platform. These optimized glycemic data sets can be analyzed more efficiently to uncover trends such as non-compliance and potential safety triggers faster than traditional diabetes monitoring models. In addition, Quintiles experts from the company’s Diabetes Center of Excellence will provide dedicated support for the offering – combining data and therapeutic expertise to drive smarter protocol design and enhance patient safety and compliance.

 “According to the International Diabetes Federation (IDF), every six seconds, a person dies from diabetes-related causes and almost half of those deaths are people under the age of 60,” said Margaret Keegan, president of Data Sciences, Safety and Regulatory Services at Quintiles. “With diabetes diagnoses on the rise, the need for innovative and accessible treatments also increases. CGM can provide a variety of in-depth measures from diabetes patients – information that can be used to enhance the way patients are treated for diabetes and why this new offering is so critical.”

Through the offering, continuous glucose measurements will be captured by a wearable sensor and wirelessly sent to a receiver, recording readings throughout the day. In the clinical trial setting, this comprehensive and timely glucose visibility has the potential to improve patient safety, accelerate clinical development and provide a basis for differentiated claims.

“We are excited to bring this new CGM offering to the market as a complement to Quintiles’ technology integration strategy,” said Sam Osman, head of Cardiac Safety Services at Quintiles. “We believe this new technology solution incorporating biosensors and wearables, which can be used across all drug development phases, will improve the way the industry tracks and improves diabetes care for patients worldwide.”

 To learn more about Quintiles Continuous Glucose Monitoring, visit quintiles.com/cgm.